Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases

Journal of Immunology Research

Volumn 2016, Issue , 2016, Pages

  Clemente, Nausicaa ^a   Raineri, Davide ^a   Cappellano, Giuseppe ^b   Boggio, Elena ^a   Favero, Francesco ^a   Soluri, Maria Felicia ^a   Dianzani, Chiara ^c   Comi, Cristoforo ^a   Dianzani, Umberto ^a   Chiocchetti, Annalisa ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, INNATE; MICE; OSTEOPONTIN; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 85008640149     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2016/7675437     Document Type: Review

References (183)

1. F. P. Ross, J. Chappel, J. I. Alvarez et al., "Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin v3 potentiate bone resorption, " Journal of Biological Chemistry, vol. 268, no. 13, pp. 9901-9907, 1993.
2. A. Oldberg, A. Franzen, and D. Heinegard, "Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence, " Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 23, pp. 8819-8823, 1986.
3. R. Patarca, G. J. Freeman, R. P. Singh et al., "Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection, " The Journal of Experimental Medicine, vol. 170, no. 1, pp. 145-161, 1989.
4. D. T. Denhardt and M. Noda, "Osteopontin expression and function: role in bone remodeling, " Journal of Cellular Biochemistry. Supplement, vol. 30-31, pp. 92-102, 1998.
5. S. K. Ramaiah and S. Rittling, "Role of osteopontin in regulating hepatic inflammatory responses and toxic liver injury, " Expert Opinion onDrugMetabolism&Toxicology, vol. 3, no. 4, pp. 519-526, 2007.
6. T. Uede, "Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases, " Pathology International, vol. 61, no. 5, pp. 265-280, 2011.
7. F. Giacopelli, N. Rosatto, M. T. Divizia, R. Cusano, G. Caridi, and R. Ravazzolo, "The first intron of the human osteopontin gene contains aC/EBP-beta-responsive enhancer, " Gene Expression, vol. 11, no. 2, pp. 95-104, 2003.
8. H. Iwasaki, Y. Shinohara, Y. Ezura et al., "Thirteen singlenucleotide polymorphisms in the human osteopontin gene identified by sequencing of the entire gene in Japanese individuals, " Journal of Human Genetics, vol. 46, no. 9, pp. 544-546, 2001.
9. S. Mochida, M. Hashimoto, A. Matsui et al., "Genetic polymorphims in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients, " Biochemical and Biophysical Research Communications, vol. 313, no. 4, pp. 1079-1085, 2004.
10. J. Glas, J. Seiderer, C. Bayrle et al., "The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease, " PLoS ONE, vol. 6, no. 12, Article ID e29309, 2011.
11. N. Barizzone, M. Marchini, F. Cappiello et al., "Association of osteopontin regulatory polymorphismswith systemic sclerosis, " Human Immunology, vol. 72, no. 10, pp. 930-934, 2011.
12. T. Miyazaki, M. Ono, W.-M. Qu et al., "Implication of allelic polymorphism of osteopontin in the development of lupus nephritis in MRL/lpr mice, " European Journal of Immunology, vol. 35, no. 5, pp. 1510-1520, 2005.
13. A. Chiocchetti, E. Orilieri, G. Cappellano et al., "The osteopontin gene +1239A/C single nucleotide polymorphism is associated with type 1 diabetes mellitus in the Italian population, " International Journal of Immunopathology and Pharmacology, vol. 23, no. 1, pp. 263-269, 2010.
14. A. Chiocchetti, M. Indelicato, T. Bensi et al., "High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation, " Blood, vol. 103, no. 4, pp. 1376-1382, 2004.
15. C. Comi, G. Cappellano, A. Chiocchetti et al., "The impact of osteopontin gene variations on multiple sclerosis development and progression, " Clinical and Developmental Immunology, vol. 2012, Article ID212893, 6 pages, 2012.
16. S. D'Alfonso, N. Barizzone, M. Giordano et al., "Two singlenucleotide polymorphisms in the 5 and 3 ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus, " Arthritis and Rheumatism, vol. 52, no. 2, pp. 539-547, 2005.
17. S. Mochida, T. Yoshimoto, S. Mimura et al., "Transgenic mice expressing osteopontin in hepatocytes as a model of autoimmune hepatitis, " Biochemical and Biophysical Research Communications, vol. 317, no. 1, pp. 114-120, 2004.
18. F. Giacopelli, R. Marciano, A. Pistorio et al., "Polymorphisms in the osteopontin promoter affect its transcriptional activity, " Physiological Genomics, vol. 15, no. 1, pp. 87-96, 2004.
19. R. Marciano, G. D'Annunzio, N. Minuto et al., "Association of alleles at polymorphic sites in the osteopontin encoding gene in young type 1 diabetic patients, " Clinical Immunology, vol. 131, no. 1, pp. 84-91, 2009.
20. T. Trivedi, B. S. Franek, S. L. Green et al., "Osteopontin alleles are associated with clinical characteristics in systemic lupus erythematosus, " Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 802581, 2011.
21. M. Niino, S. Kikuchi, T. Fukazawa, I. Yabe, and K. Tashiro, "Genetic polymorphisms of osteopontin in association withmultiple sclerosis in Japanese patients, " Journal of Neuroimmunology, vol. 136, no. 1-2, pp. 125-129, 2003.
22. A. C. Forton, M. A. Petri, D. Goldman, and K. E. Sullivan, "An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus, " Human Mutation, vol. 19, no. 4, p. 459, 2002.
23. K. Kikuchi, A. Tanaka, H. Miyakawa et al., "Eta-1/osteopontin genetic polymorphism and primary biliary cirrhosis, " Hepatology Research, vol. 26, no. 2, pp. 87-90, 2003.
24. M. Chu, P. Yang, S. Hou, F. Li, Y. Chen, andA. Kijlstra, "Behçet's disease exhibits an increased osteopontin serum level in active stage but no association with osteopontin and its receptor gene polymorphisms, " Human Immunology, vol. 72, no. 6, pp. 525-529, 2011.
25. Y. H. Lee and G. G. Song, "Correlation between circulating osteopontin level in systemic lupus erythematosus and disease activity and associations between osteopontin polymorphisms and disease susceptibility: A meta-analysis, " Lupus, 2016.
26. E. Kläning, B. Christensen, E. S. Sørensen, T. Vorup-Jensen, and J. K. Jensen, "Osteopontin bindsmultiple calciumionswith high affinity and independently of phosphorylation status, " Bone, vol. 66, pp. 90-95, 2014.
27. M. F. Young, J. M. Kerr, J. D. Termine et al., "cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN), " Genomics, vol. 7, no. 4, pp. 491-502, 1990.
28. J. D. Coombes, M. Swiderska-Syn, L. Dollé et al., "Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice, " Gut, vol. 64, pp. 1120-1131, 2014.
29. M. Nemir, M. W. DeVouge, and B. B. Mukherjee, "Normal rat kidney cells secrete both phosphorylated and nonphosphorylated forms of osteopontin showing different physiological properties, "The Journal of Biological Chemistry, vol. 264, no. 30, pp. 18202-18208, 1989.
30. G. F. Weber, S. Zawaideh, S. Hikita, V. A. Kumar, H. Cantor, and S. Ashkar, "Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation, " Journal of Leukocyte Biology, vol. 72, no. 4, pp. 752-761, 2002.
31. V. Shanmugam, I. Chackalaparampil, G. C. Kundu, A. B. Mukherjee, and B. B. Mukherjee, "Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells, " Biochemistry, vol. 36, no. 19, pp. 5729-5738, 1997.
32. B. Christensen, C. C. Kazanecki, T. E. Petersen, S. R. Rittling, D. T. Denhardt, and E. S. Sørensen, "Cell type-specific posttranslationalmodifications of mouse osteopontin are associated with different adhesive properties, " The Journal of Biological Chemistry, vol. 282, no. 27, pp. 19463-19472, 2007.
33. K. Singh, M. W. DeVouge, and B. B. Mukherjee, "Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated forms of osteopontin secreted by normal rat kidney cells, " The Journal of Biological Chemistry, vol. 265, no. 30, pp. 18696-18701, 1990.
34. B. He, M. Mirza, andG. F. Weber, "An osteopontin splice variant induces anchorage independence in human breast cancer cells, " Oncogene, vol. 25, no. 15, pp. 2192-2202, 2006.
35. S. Denda, U. Müller, K. L. Crossin, H. P. Erickson, and L. F. Reichardt, "Utilization of a soluble integrin-alkaline phosphatase chimera to characterize integrin 8 1 receptor interactions with tenascin: murine 8 1 binds to the RGD site in tenascin-C fragments, but not to native tenascin-C, " Biochemistry, vol. 37, no. 16, pp. 5464-5474, 1998.
36. D. D. Hu, J. R. Hoyer, and J. W. Smith, "Ca2+ suppresses cell adhesion to osteopontin by attenuating binding affinity for integrin v3, "The Journal of Biological Chemistry, vol. 270, no. 17, pp. 9917-9925, 1995.
37. Y. Yokosaki, K. Tanaka, F. Higashikawa, K. Yamashita, and A. Eboshida, "Distinct structural requirements for binding of the integrins v6, v3, v5, 51 and 91 to osteopontin, " Matrix Biology, vol. 24, no. 6, pp. 418-427, 2005.
38. P. M. Green, S. B. Ludbrook, D. D. Miller, C. M. T. Horgan, and S. T. Barry, "Structural elements of the osteopontin SVVYGLR motif important for the interaction with 4 integrins, " FEBS Letters, vol. 503, no. 1, pp. 75-79, 2001.
39. K. Ito, S. Kon, Y. Nakayama et al., "The differential amino acid requirement within osteopontin in 4 and 9 integrinmediated cell binding and migration, " Matrix Biology, vol. 28, no. 1, pp. 11-19, 2009.
40. G. Murugaiyan, A. Mittal, and H. L. Weiner, "Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis, " The Journal of Immunology, vol. 181, no. 11, pp. 7480-7488, 2008.
41. H. Guan, P. S. Nagarkatti, and M. Nagarkatti, "Role of CD44 in the differentiation of Th1 and Th2 cells: CD44-deficiency enhances the development of Th2 effectors in response to sheep RBC and chicken ovalbumin, " Journal of Immunology, vol. 183, no. 1, pp. 172-180, 2009.
42. E. Boggio, C. Dianzani, C. L. Gigliotti et al., "Thrombin cleavage of osteopontin modulates its activities in human cells in vitro and mouse experimental autoimmune encephalomyelitis in vivo, " Journal of Immunology Research, vol. 2016, Article ID 9345495, 13 pages, 2016.
43. G. Platzer, A. Schedlbauer, A. Chemelli et al., "The metastasisassociated extracellular matrix protein osteopontin forms transient structure in ligand interaction sites, " Biochemistry, vol. 50, no. 27, pp. 6113-6124, 2011.
44. Metastasis, Osteopontin, Heparin Cooling Inflammation Blog, http://coolinginflammation. blogspot. it/2008/10/metastasisosteopontin-heparin. html.
45. R. Agnihotri, H. C. Crawford, H. Haro, L. M. Matrisian, M. C. Havrda, and L. Liaw, "Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin), "The Journal of Biological Chemistry, vol. 276, no. 30, pp. 28261-28267, 2001.
46. H. Masuda, Y. Takahashi, S. Asai, and T. Takayama, "Distinct gene expression of osteopontin in patients with ulcerative colitis, " Journal of Surgical Research, vol. 111, no. 1, pp. 85-90, 2003.
47. A. G. DaSilva, L. Liaw, and V. W. Yong, "Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 mice, " American Journal of Pathology, vol. 177, no. 3, pp. 1448-1458, 2010.
48. P. Beltrao, P. Bork, N. J. Krogan, and V. Van Noort, "Evolution and functional cross-talk of protein post-translational modifications, " Molecular Systems Biology, vol. 9, no. 1, article 714, 2013.
49. A. M. Butt, D. Feng, M. Idrees, Y. Tong, and J. Lu, "Computational identification and modeling of crosstalk between phosphorylation, O-glycosylation and methylation of FoxO3 and implications for cancer therapeutics, " International Journal of Molecular Sciences, vol. 13, no. 3, pp. 2918-2938, 2012.
50. M. Keykhosravani, A. Doherty-Kirby, C. Zhang et al., "Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry, " Biochemistry, vol. 44, no. 18, pp. 6990-7003, 2005.
51. B. Christensen, M. S. Nielsen, K. F. Haselmann, T. E. Petersen, and E. S. Sørensen, "Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications, " Biochemical Journal, vol. 390, no. 1, pp. 285-292, 2005.
52. H. Rangaswami, A. Bulbule, and G. C. Kundu, "Osteopontin: role in cell signaling and cancer progression, " Trends in Cell Biology, vol. 16, no. 2, pp. 79-87, 2006.
53. H. Li, H. Shen, G. Yan et al., "Site-specific structural characterization of O-glycosylation and identification of phosphorylation sites of recombinant osteopontin, " Biochimica et Biophysica Acta-Proteins and Proteomics, vol. 1854, no. 6, pp. 581-591, 2015.
54. Y. Kariya, M. Kanno, K. Matsumoto-Morita, M. Konno, Y. Yamaguchi, and Y. Hashimoto, "Osteopontin O-glycosylation contributes to its phosphorylation and cell-adhesion properties, " The Biochemical Journal, vol. 463, no. 1, pp. 93-102, 2014.
55. A. L. Boskey, M. Maresca, W. Ullrich, S. B. Doty, W. T. Butler, and C. W. Prince, "Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel, " Bone and Mineral, vol. 22, no. 2, pp. 147-159, 1993.
56. A. L. Boskey, "Osteopontin and related phosphorylated sialoproteins: effects on mineralization, " Annals of the New York Academy of Sciences, vol. 760, pp. 249-256, 1995.
57. G. K. Hunter, P. V. Hauschka, A. R. Poole, L. C. Rosenberg, and H. A. Goldberg, "Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins, " Biochemical Journal, vol. 317, no. 1, pp. 59-64, 1996.
58. H. A. Goldberg, K. J. Warner, M. C. Li, andG. K. Hunter, "Binding of bone sialoprotein, osteopontin and synthetic polypeptides to hydroxyapatite, " Connective Tissue Research, vol. 42, no. 1, pp. 25-37, 2001.
59. S. Jono, C. Peinado, and C. M. Giachelli, "Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification, " Journal of Biological Chemistry, vol. 275, no. 26, pp. 20197-20203, 2000.
60. A. L. Boskey, S. B. Doty, V. Kudryashov, P. Mayer-Kuckuk, R. Roy, and I. Binderman, "Modulation of extracellular matrix protein phosphorylation alters mineralization in differentiating chick limb-bud mesenchymal cell micromass cultures, " Bone, vol. 42, no. 6, pp. 1061-1071, 2008.
61. W. N. Addison, F. Azari, E. S. Sørensen, M. T. Kaartinen, andM. D. McKee, "Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity, " Journal of Biological Chemistry, vol. 282, no. 21, pp. 15872-15883, 2007.
62. W. Jahnen-Dechent, C. Schäfer, M. Ketteler, and M. D. McKee, "Mineral chaperones: A role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification, " Journal of Molecular Medicine, vol. 86, no. 4, pp. 379-389, 2008.
63. A. Gericke, C. Qin, L. Spevak et al., "Importance of phosphorylation for osteopontin regulation of biomineralization, " Calcified Tissue International, vol. 77, no. 1, pp. 45-54, 2005.
64. A. L. Boskey, L. Spevak, E. Paschalis, S. B. Doty, and M. D. McKee, "Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone, " Calcified Tissue International, vol. 71, no. 2, pp. 145-154, 2002.
65. Y. Matsui, S. R. Rittling, H. Okamoto et al., "Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 6, pp. 1029-1034, 2003.
66. J. A. Wesson, R. J. Johnson, M. Mazzali et al., "Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules, " Journal of the American Society of Nephrology, vol. 14, no. 1, pp. 139-147, 2003.
67. A. L. Boskey, B. Christensen, H. Taleb, and E. S. Sørensen, "Post-translational modification of osteopontin: effects on in vitro hydroxyapatite formation and growth, " Biochemical and Biophysical Research Communications, vol. 419, no. 2, pp. 333-338, 2012.
68. T. Nagata, R. Todescan, H. A. Goldberg, Q. Zhang, and J. Sodek, "Sulphation of secreted phosphoprotein I (SPPI, osteopontin) is associated with mineralized tissue formation, " Biochemical and Biophysical Research Communications, vol. 165, no. 1, pp. 234-240, 1989.
69. R. Zohar, W. Lee, P. Arora, S. Cheifetz, C. McCulloch, and J. Sodek, "Single cell analysis of intracellular osteopontin in osteogenic cultures of fetal rat calvarial cells, " Journal of Cellular Physiology, vol. 170, no. 1, pp. 88-100, 1997.
70. A. Junaid, M. C. Moon, G. E. J. Harding, and P. Zahradka, "Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1, " American Journal of Physiology-Cell Physiology, vol. 292, no. 2, pp. C919-C926, 2007.
71. H. Cantor and M. L. Shinohara, "Regulation of T-helper-cell lineage development by osteopontin: The inside story, " Nature Reviews Immunology, vol. 9, no. 2, pp. 137-141, 2009.
72. M. L. Shinohara, M. Jansson, E. S. Hwang, M. B. F. Werneck, L. H. Glimcher, and H. Cantor, "T-bet-dependent expression of osteopontin contributes to T cell polarization, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 47, pp. 17101-17106, 2005.
73. J. W. Leavenworth, B. Verbinnen, J. Yin, H. Huang, and H. Cantor, "A p85-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells, " Nature Immunology, vol. 16, no. 1, pp. 96-106, 2015.
74. R. Zohar, N. Suzuki, K. Suzuki et al., "Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration, " Journal of Cellular Physiology, vol. 184, no. 1, pp. 118-130, 2000.
75. B. Zhu, K. Suzuki, H. A. Goldberg et al., "Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin, " Journal of Cellular Physiology, vol. 198, no. 1, pp. 155-167, 2004.
76. K. Suzuki, S. Takeyama, Y. Sakai, S. Yamada, and H. Shinoda, "Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts, " Journal of Pharmacological Sciences, vol. 100, no. 3, pp. 189-194, 2006.
77. K. Masutani, M. Akahoshi, K. Tsuruya et al., "Predominance of Th1 immune response in diffuse proliferative lupus nephritis, " Arthritis and Rheumatism, vol. 44, no. 9, pp. 2097-2106, 2001 (Lithuanian).
78. Y. Katagiri, K. Mori, T. Hara, K. Tanaka, M. Murakami, and T. Uede, "Functional analysis of the osteopontinmolecule, " Annals of the New York Academy of Sciences, vol. 760, pp. 371-374, 1995.
79. D. Chabas, S. E. Baranzini, D. Mitchell et al., "The influence of the proinflammatory cytokine, osteopontin, on autoimmunedemyelinating disease, " Science, vol. 294, no. 5547, pp. 1731-1735, 2001.
80. S. Ohsima, N. Yamaguchi, K. Nishioka et al., "Enhanced local production of osteopontin in rheumatoid joints, " Journal of Rheumatology, vol. 29, pp. 2061-2067, 2002.
81. R. Mishima, F. Takeshima, T. Sawai et al., "High plasma osteopontin levels inpatientswith inflammatorybowel disease, " Journal of Clinical Gastroenterology, vol. 41, no. 2, pp. 167-172, 2007.
82. J. Iizuka, Y. Katagiri, N. Tada et al., "Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies, " Laboratory Investigation, vol. 78, no. 12, pp. 1523-1533, 1998.
83. M. Braitch and C. S. Constantinescu, "The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS), " Inflammation and Allergy-Drug Targets, vol. 9, no. 4, pp. 249-256, 2010.
84. K. Yumoto, M. Ishijima, S. R. Rittling et al., "Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 7, pp. 4556-4561, 2002.
85. T. Nomiyama, D. Perez-Tilve, D. Ogawa et al., "Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice, " Journal of Clinical Investigation, vol. 117, no. 10, pp. 2877-2888, 2007.
86. M. Kitamura, K. Iwabuchi, N. Kitaichi et al., "Osteopontin aggravates experimental autoimmune uveoretinitis in mice, " Journal of Immunology, vol. 178, no. 10, pp. 6567-6572, 2007.
87. W.-K. Syn, S. S. Choi, E. Liaskou et al., "Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression innonalcoholic steatohepatitis, " Hepatology, vol. 53, no. 1, pp. 106-115, 2011.
88. O. Morales-Ibanez, M. Domnguez, S. H. Ki et al., "Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis, " Hepatology, vol. 58, no. 5, pp. 1742-1756, 2013.
89. K. Heilmann, U. Hoffmann, E. Witte et al., "Osteopontin as twosided mediator of intestinal inflammation, " Journal of Cellular and Molecular Medicine, vol. 13, no. 6, pp. 1162-1174, 2009.
90. S. Husain-Krautter, J. M. Kramer, W. Li, B. Guo, and T. L. Rothstein, "The osteopontin transgenic mouse is a new model for SjÖgren's syndrome, " Clinical Immunology, vol. 157, no. 1, pp. 30-42, 2015.
91. D. F. Frenzel, L. Borkner, J. Scheurmann, K. Singh, K. Scharffetter-Kochanek, and J. M. Weiss, "Osteopontin deficiency affects imiquimod-induced psoriasis-like murine skin inflammation and lymphocyte distribution in skin, draining lymph nodes and spleen, " Experimental Dermatology, vol. 24, no. 4, pp. 305-307, 2015.
92. J. Bentham, D. L. Morris, D. S. Cunninghame Graham et al., "Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus, " Nature Genetics, vol. 47, no. 12, pp. 1457-1464, 2015.
93. E. A. Stahl, S. Raychaudhuri, E. F. Remmers et al., "Genomewide association study meta-analysis identifies seven new rheumatoid arthritis risk loci, " Nature Genetics, vol. 42, no. 6, pp. 508-514, 2010.
94. C. Cotsapas, B. F. Voight, E. Rossin et al., "Pervasive sharing of genetic effects in autoimmune disease, " PLoS Genetics, vol. 7, no. 8, Article ID e1002254, 2011.
95. S. Alfadhli, A. A. M. Ghanem, and R. Nizam, "Genome-wide differential expression reveals candidate genes involved in the pathogenesis of lupus and lupus nephritis, " International Journal of Rheumatic Diseases, vol. 19, no. 1, pp. 55-64, 2016.
96. X.-F. Pan, J.-Q. Gu, andZ.-Y. Shan, "Patientswith systemic lupus erythematosus have higher prevalence of thyroid autoantibodies: A systematic review and meta-analysis, " PLOS ONE, vol. 10, no. 4, Article ID e0123291, 2015.
97. S. Iwata and Y. Tanaka, "B-cell subsets, signaling and their roles in secretion of autoantibodies, " Lupus, vol. 25, no. 8, pp. 850-856, 2016.
98. R. Patarca, F.-Y. Wei, P. Singh, M. I. Morasso, and H. Cantor, "Dysregulated expression of the T cell cytokine Eta-1 in CD4-8-lymphocytes during the development of murine autoimmune disease, " Journal of Experimental Medicine, vol. 172, no. 4, pp. 1177-1183, 1990.
99. A. N. Theofilopoulos and F. J. Dixon, "Etiopathogenesis of murine SLE, " Immunological Reviews, vol. 55, pp. 179-216, 1981.
100. P. L. Cohen and R. A. Eisenberg, "Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease, " Annual Review of Immunology, vol. 9, no. 1, pp. 243-269, 1991.
101. G. F. Weber and H. Cantor, "Differential roles of osteopontin/ Eta-1 in early and late lpr disease, " Clinical and Experimental Immunology, vol. 126, no. 3, pp. 578-583, 2001.
102. M. Aricò, E. Boggio, V. Cetica et al., "Variations of the UNC13D gene in patients with autoimmune lymphoproliferative syndrome, " PLoS ONE, vol. 8, no. 7, Article ID e68045, 2013.
103. R. Clementi, A. Chiocchetti, G. Cappellano et al., "Variations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective Fas function, " Blood, vol. 108, no. 9, pp. 3079-3084, 2006.
104. M. Ono, T. Yamamoto, and M. Nose, "Allelic difference in the nucleotide sequence of the Eta-1/Op gene transcript, "Molecular Immunology, vol. 32, no. 6, pp. 447-448, 1995.
105. E. Boggio, M. Indelicato, E. Orilieri et al., "Role of tissue inhibitor ofmetalloproteinases-1 in the development of autoimmune lymphoproliferation, " Haematologica, vol. 95, no. 11, pp. 1897-1904, 2010.
106. E. Boggio, N. Clemente, A. Mondino et al., "IL-17 protects T cells from apoptosis and contributes to development of ALPSlike phenotypes, " Blood, vol. 123, no. 8, pp. 1178-1186, 2014.
107. C. K. Wong, L. C. W. Lit, L. S. Tam, E. K. Li, and C. W. K. Lam, "Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus, " Rheumatology, vol. 44, no. 5, pp. 602-606, 2005.
108. O. J. Rullo, J. M. P. Woo, M. F. Parsa et al., "Plasma levels of osteopontin identify patients at risk for organ damage in systemic lupus erythematosus, " Arthritis Research & Therapy, vol. 15, no. 1, article R18, 2013.
109. K. Masutani, M. Akahoshi, K. Tsuruya et al., "Predominance of Th1 immune response in diffuse proliferative lupus nephritis, " Arthritis & Rheumatism, vol. 44, no. 9, pp. 2097-2106, 2001.
110. M. Quaglia, A. Chiocchetti, T. Cena et al., "Osteopontin circulating levels correlate with renal involvement in systemic lupus erythematosus and are lower in ACE inhibitor-treated patients, " Clinical Rheumatology, vol. 33, no. 9, pp. 1263-1271, 2014.
111. S. N. Kariuki, J. G. Moore, K. A. Kirou, M. K. Crow, T. O. Utset, and T. B. Niewold, "Age-and gender-specific modulation ofserum osteopontin and interferon-by osteopontin genotype in systemic lupus erythematosus, " Genes & Immunity, vol. 10, no. 5, pp. 487-494, 2009.
112. Y. Tanino, N. Hizawa, S. Konno et al., "Sequence variants of the secreted phosphoprotein 1 gene are associated with total serum immunoglobulin E levels in a Japanese population, " Clinical & Experimental Allergy, vol. 36, no. 2, pp. 219-225, 2006.
113. S. Han, J. M. Guthridge, I. T. W. Harley et al., "Osteopontin and Systemic Lupus Erythematous association: A probable gene-gender interaction, " PLOS ONE, vol. 3, no. 3, Article ID e0001757, 2008.
114. D. T. Denhardt, M. Noda, A. W. O'Regan, D. Pavlin, and J. S. Berman, "Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival, " Journal of Clinical Investigation, vol. 107, no. 9, pp. 1055-1061, 2001.
115. S. Salimi, M. Noora, S. Nabizadeh et al., "Association of the osteopontin rs1126616 polymorphism and a higher serum osteopontin level with lupus nephritis, " Biomedical Reports, vol. 4, no. 3, pp. 355-360, 2016.
116. J. Merszei, J. Wu, L. Torres et al., "Osteopontin overproduction is associated with progression of glomerular fibrosis in a ratmodel of anti-glomerular basement membrane glomerulonephritis, " AmericanJournal of Nephrology, vol. 32, no. 3, pp. 262-271, 2010.
117. C. Zhou, J. Wu, L. Torres et al., "Blockade of osteopontin inhibits glomerular fibrosis in a model of anti-glomerular basement membrane glomerulonephritis, " American Journal of Nephrology, vol. 32, no. 4, pp. 324-331, 2010.
118. T. Wolak, H. Kim, Y. Ren, J. Kim, N. D. Vaziri, and S. B. Nicholas, "Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney, " Kidney International, vol. 76, no. 1, pp. 32-43, 2009.
119. C. M. Giachelli, L. Liaw, C. E. Murry, S. M. Schwartz, and M. Almeida, "Osteopontin expression in cardiovascular diseases, " Annals of the New York Academy of Sciences, vol. 760, pp. 109-126, 1995.
120. D. Bruemmer, A. R. Collins, G. Noh et al., "Angiotensin IIaccelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice, " The Journal of Clinical Investigation, vol. 112, no. 9, pp. 1318-1331, 2003.
121. B. G. Weinshenker, "The natural history of multiple sclerosis, " Neurologic Clinics, vol. 13, no. 1, pp. 119-146, 1995.
122. S. A. Lund, C. M. Giachelli, and M. Scatena, "The role of osteopontin in inflammatory processes, " Journal of Cell Communication and Signaling, vol. 3, no. 3-4, pp. 311-322, 2009.
123. M. H. J. Vogt, L. Lopatinskaya, M. Smits, C. H. Polman, and L. Nagelkerken, "Elevated osteopontin levels in active relapsingremitting multiple sclerosis, " Annals of Neurology, vol. 53, no. 6, pp. 819-822, 2003.
124. C. Sinclair, M. Mirakhur, J. Kirkt, M. Farrell, and S. McQuaid, "Up-regulation of osteopontin and-crystallin in the normalappearing white matter of multiple sclerosis: An immunohistochemical study utilizing tissue microarrays, " Neuropathology and Applied Neurobiology, vol. 31, no. 3, pp. 292-303, 2005.
125. M. Comabella, I. Pericot, R. Goertsches et al., "Plasma osteopontin levels in multiple sclerosis, " Journal of Neuroimmunology, vol. 158, no. 1-2, pp. 231-239, 2005.
126. L. Börnsen, M. Khademi, T. Olsson, P. S. Sørensen, and F. Sellebjerg, "Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis, " Multiple Sclerosis Journal, vol. 17, no. 1, pp. 32-42, 2011.
127. M. Carecchio and C. Comi, "The role of osteopontin in neurodegenerative diseases, " Journal of Alzheimer's Disease, vol. 25, no. 2, pp. 179-185, 2011.
128. E. M. Hur, S. Youssef, M. E. Haws, S. Y. Zhang, R. A. Sobel, and L. Steinman, "Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells, " Nature Immunology, vol. 8, no. 1, pp. 74-83, 2007.
129. R. K. Han, Y. F. Cheng, S. S. Zhou et al., "Increased circulating Th17 cell populations and elevated CSF osteopontin and il-17 concentrations in patients with Guillain-Barré syndrome, " Journal of Clinical Immunology, vol. 34, no. 1, pp. 94-103, 2014.
130. M. Chen, G. Chen, H. Nie et al., "Regulatory effects of IFN-on production of osteopontin and IL-17 by CD4+ T Cells inMS, " European Journal of Immunology, vol. 39, no. 9, pp. 2525-2536, 2009.
131. S. Cailier, L. F. Baranzini, A. Swerdlin et al., "Multiple Sclerosis Genetics Group. Osteopontin polymorphisms and disease course in multiple sclerosis, " Genes and Immunity, vol. 4, no. 4, pp. 312-315, 2003.
132. A. Chiocchetti, C. Comi, M. Indelicato et al., "Osteopontin gene haplotypes correlate with multiple sclerosis development and progression, " Journal of Neuroimmunology, vol. 163, no. 1-2, pp. 172-178, 2005.
133. M. Jansson, V. Panoutsakopoulou, J. Baker, L. Klein, and H. Cantor, "Cutting edge: Attenuated experimental autoimmune encephalomyelitis in Eta-1/osteopontin-deficient mice, " Journal of Immunology, vol. 168, no. 5, pp. 2096-2099, 2002.
134. H. Neumann, I. M. Medana, J. Bauer, and H. Lassmann, "Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases, " Trends in Neurosciences, vol. 25, no. 6, pp. 313-319, 2002.
135. L. Steinman, "Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab, " Nature Reviews Drug Discovery, vol. 4, no. 6, pp. 510-518, 2005.
136. L. Steinman, "Some misconceptions about understanding autoimmunity through experiments with knockouts, " Journal of Experimental Medicine, vol. 185, no. 12, pp. 2039-2041, 1997.
137. A. O'Regan and J. S. Berman, "Osteopontin: A key cytokine in cell-mediated and granulomatous inflammation, " International Journal of Experimental Pathology, vol. 81, no. 6, pp. 373-390, 2000.
138. M. Hashimoto, D. Sun, S. R. Rittling, D. T. Denhardt, and W. Young, "Osteopontin-deficient mice exhibit less inflammation, greater tissue damage, and impaired locomotor recovery from spinal cord injury compared with wild-type controls, " Journal of Neuroscience, vol. 27, no. 13, pp. 3603-3611, 2007.
139. R. Selvaraju, L. Bernasconi, C. Losberger et al., "Osteopontin is upregulated during in vivo demyelination and remyelination and enhancesmyelinformation invitro, "Molecular and Cellular Neuroscience, vol. 25, no. 4, pp. 707-721, 2004.
140. M. Rabenstein, J. Hucklenbroich, A. Willuweit et al., "Osteopontin mediates survival, proliferation and migration of neural stem cells through the chemokine receptor CXCR4, " Stem Cell Research &Therapy, vol. 6, article 99, 2015.
141. M. D. McKee and A. Nanci, "Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair, "Microscopy Research and Technique, vol. 33, no. 2, pp. 141-164, 1996.
142. M. G. Attur, M. N. Dave, S. Stuchin et al., "Osteopontin: An intrinsic inhibitor of inflammation in cartilage, " Arthritis and Rheumatism, vol. 44, no. 3, pp. 578-584, 2001.
143. F. Zhang, W. Luo, Y. Li, S. Gao, and G. Lei, "Role of osteopontin in rheumatoid arthritis, " Rheumatology International, vol. 35, no. 4, pp. 589-595, 2015.
144. S. G. Gao, K. H. Li, K. B. Zeng, M. Tu, M. Xu, and G. H. Lei, "Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients, " Osteoarthritis and Cartilage, vol. 18, no. 1, pp. 82-87, 2010.
145. K. Suzuki, B. Zhu, S. R. Rittling et al., "Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts, " Journal of Bone and Mineral Research, vol. 17, no. 8, pp. 1486-1497, 2002.
146. S. Ohshima, H. Kobayashi, N. Yamaguchi et al., "Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis, " Arthritis & Rheumatism, vol. 46, no. 4, pp. 1094-1101, 2002.
147. A. M. Badger, S. Blake, R. Kapadia et al., "Disease-modifying activity of SB 273005, an orally active, nonpeptide v3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis, " Arthritis and Rheumatism, vol. 44, no. 1, pp. 128-137, 2001.
148. N. Yamamoto, F. Sakai, S. Kon et al., "Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis, " The Journal of Clinical Investigation, vol. 112, no. 2, pp. 181-188, 2003.
149. M. Yamaga, K. Tsuji, K. Miyatake et al., "Osteopontin level in synovial fluid is associated with the severity of joint pain and cartilage degradation after anterior cruciate ligament rupture, " PLoS ONE, vol. 7, no. 11, Article ID e49014, 2012.
150. S. A. Sharif, X. Du, T. Myles et al., "Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritis, " Arthritis and Rheumatism, vol. 60, no. 10, pp. 2902-2912, 2009.
151. Y. Take, K. Nakata, J. Hashimoto et al., "Specifically modified osteopontin in rheumatoid arthritis fibroblast-like synoviocytes supports interaction with B cells and enhances production of interleukin-6, " Arthritis&Rheumatism, vol. 60, no. 12, pp. 3591-3601, 2009.
152. G. Chen, X. Zhang, R. Li et al., "Role of osteopontin in synovial Th17 differentiation in rheumatoid arthritis, " Arthritis and Rheumatism, vol. 62, no. 10, pp. 2900-2908, 2010.
153. E. Urcelay, A. Martnez, A. Mas-Fontaoet al., "Osteopontingene polymorphisms in spanish patients with rheumatoid arthritis, " The Journal of Rheumatology, vol. 32, no. 3, pp. 405-409, 2005.
154. G. Xu, W. Sun, D. He et al., "Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism, " The Journal of Rheumatology, vol. 32, no. 3, pp. 410-416, 2005.
155. F. Ceccarelli, S. D'Alfonso, C. Perricone et al., "The role of eight polymorphisms in three candidate genes in determining the susceptibility, phenotype, and response to anti-TNF therapy in patients with rheumatoid arthritis, " Clinical and Experimental Rheumatology, vol. 30, no. 6, pp. 939-942, 2012.
156. K. Izumi, Y. Kaneko, M. Hashizume, K. Yoshimoto, and T. Takeuchi, "Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not infliximab in biologic-Näve patients with rheumatoid arthritis: A singlecenter prospective study at 1 year (the Keio First-Bio Cohort study), " PLOS ONE, vol. 10, no. 12, Article ID e0145468, 2015.
157. C. Cheng, S. Gao, and G. Lei, "Association of osteopontin with osteoarthritis, " Rheumatology International, vol. 34, no. 12, pp. 1627-1632, 2014.
158. S. Honsawek, A. Tanavalee, M. Sakdinakiattikoon, M. Chayanupatkul, and P. Yuktanandana, "Correlation of plasma and synovial fluid osteopontinwith disease severity in knee osteoarthritis, " Clinical Biochemistry, vol. 42, no. 9, pp. 808-812, 2009.
159. T. M. Griffin and F. Guilak, "The role of mechanical loading in the onset and progression of osteoarthritis, " Exercise and Sport Sciences Reviews, vol. 33, no. 4, pp. 195-200, 2005.
160. F.-J. Zhang, W.-B. Yu, W. Luo, S.-G. Gao, Y.-S. Li, and G.-H. Lei, "Effect of osteopontin on TIMP-1 and TIMP-2 mRNA in chondrocytes of human knee osteoarthritis in vitro, " Experimental andTherapeutic Medicine, vol. 8, no. 2, pp. 391-394, 2014.
161. R. C. Billinghurst, L. Dahlberg, M. Ionescu et al., "Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage, "The Journal of Clinical Investigation, vol. 99, no. 7, pp. 1534-1545, 1997.
162. M. G. Attur, I. R. Patel, R. N. Patel, S. B. Abramson, and A. R. Amin, "Autocrine production of IL-1 by human osteoarthritisaffected cartilage and differential regulation of endogenous nitric oxide, IL-6, prostaglandin E2, and IL-8, " Proceedings of the Association of American Physicians, vol. 110, no. 1, pp. 65-72, 1998.
163. D. Daneman, "Type 1 diabetes, " The Lancet, vol. 367, no. 9513, pp. 847-858, 2006.
164. I. Barchetta, C. Alessandri, L. Bertoccini et al., "Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile, " European Journal of Endocrinology, vol. 174, no. 2, pp. 187-192, 2016.
165. M. Talat, L. Sherief, H. El-Saadany, A. Ahmed, R. Salah, andM. sakr, "The role of osteopontin in the pathogenesis and complication of type 1 diabetes mellitus in children and adolescents, " Journal of Clinical Research in Pediatric Endocrinology, 2016.
166. D. Gordin, C. Forsblom, N. M. Panduru et al., "Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular disease, and all-cause mortality in patients with type 1 diabetes, " Diabetes Care, vol. 37, no. 9, pp. 2593-2600, 2014.
167. A. Fierabracci, P. A. Biro, Y. Yiangou et al., "Osteopontin is an autoantigen of the somatostatin cells in human islets: identification by screening random peptide libraries with sera of patients with insulin-dependent diabetes mellitus, " Vaccine, vol. 18, no. 3-4, pp. 342-354, 1999.
168. Y. H. Wang, M. S. Zhao, andY. Zhao, "Expressionofosteopontin in labial glands of patients with primary SjÖgren's syndrome, " Beijing Da Xue Xue Bao, vol. 44, no. 2, pp. 236-239, 2012.
169. G.-L. Wu, N.-Y. Wu, T.-Y. Li, Y.-S. Fan, G.-Y. Yu, and W.-W. Lu, "Effect of Chinese herbal medicines for nourishing yin, supplementing qi, and activating blood on reproductive endocrine activity and immune functions in patients with primary Sjogren's syndrome, " Chinese Journal of Integrative Medicine, vol. 21, no. 10, pp. 778-783, 2015.
170. S. Cha, A. B. Peck, and M. G. Humphreys-Beher, "Progress in understanding autoimmune exocrinopathy using the nonobese diabetic mouse: An update, " Critical Reviews in Oral Biology and Medicine, vol. 13, no. 1, pp. 5-16, 2002.
171. N. Gassler, F. Autschbach, S. Gauer et al., "Expression of osteopontin (Eta-1) in Crohn disease of the terminal ileum, " Scandinavian Journal of Gastroenterology, vol. 37, no. 11, pp. 1286-1295, 2002.
172. J. Agnholt, J. Kelsen, L. Schack, C. L. Hvas, J. F. Dahlerup, and E. S. Sørensen, "Osteopontin, a protein with cytokine-likeproperties, is associated with inflammation in Crohn's disease, " Scandinavian Journal of Immunology, vol. 65, no. 5, pp. 453-460, 2007.
173. J. N. Gordon and T. T. MacDonald, "Osteopontin: A new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn's disease, " Gut, vol. 54, no. 9, pp. 1213-1215, 2005.
174. T. Sato, T. Nakai, N. Tamura et al., "Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response, " Gut, vol. 54, no. 9, pp. 1254-1262, 2005.
175. S. Komine-Aizawa, H. Masuda, T. Mazaki, M. Shiono, S. Hayakawa, and T. Takayama, "Plasma osteopontin predicts inflammatory bowel disease activities, " International Surgery, vol. 100, no. 1, pp. 38-43, 2015.
176. K. Heilmann, U. Hoffmann, E. Witte et al., "Osteopontin as twosided mediator of intestinal inflammation, " Journal of Cellular and Molecular Medicine, vol. 13, no. 6, pp. 1162-1174, 2009.
177. M. Sakata, J.-I. Tsuruha, K. Masuko-Hongo et al., "Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis, " Journal of Rheumatology, vol. 28, no. 7, pp. 1492-1495, 2001.
178. G. Cappellano, E. Orilieri, A. D. Woldetsadik et al., "Anticytokineautoantibodies in autoimmune diseases, " American Journal of Clinical and Experimental Immunology, vol. 1, no. 2, pp. 136-146, 2012.
179. L. Steinman, S. Youssef, N. Van Venrooij et al., "Response to Comment on 'The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease', " Science, vol. 299, article 1845, 2003.
180. M. J. H. Boumans, J. G. A. Houbiers, P. Verschueren et al., "Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: A randomised, placebo controlled, proof-of-concept study, " Annals of the Rheumatic Diseases, vol. 71, no. 2, pp. 180-185, 2012.
181. S. Kon, Y. Yokosaki, M. Maeda et al., "Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences, " Journal of Cellular Biochemistry, vol. 84, no. 2, pp. 420-432, 2002.
182. C.-M. Su, Y.-C. Chiang, C.-Y. Huang, C.-J. Hsu, Y.-C. Fong, and C.-H. Tang, "Osteopontin promotes oncostatin M production in human osteoblasts: implication of rheumatoid arthritis therapy, " The Journal of Immunology, vol. 195, no. 7, pp. 3355-3364, 2015.
183. D. Iwata, M. Kitamura, N. Kitaichi et al., "Prevention of experimental autoimmune uveoretinitis by blockade of osteopontin with small interferingRNA, " Experimental Eye Research, vol. 90, no. 1, pp. 41-48, 2010.